SA Asks: How could Trump's new executive order impact vaccine makers?

President Donald Trump's recent executive order on childhood vaccines has sparked a debate over public health, parental choice, and the science behind the directive. The order proposes altering the U.S. childhood vaccine schedule and breaking up the combined MMR vaccine into multiple shots. Immunologists argue that the order goes against scientific consensus and evidence-based recommendations.

The more pressing issue with the order, however, may be its effect on vaccine policy. For years, the U.S. relied on a transparent process involving scientists, physicians, and public health experts who reviewed evidence and developed immunization guidelines. This system allowed for constructive debate and improvement of policies. However, replacing expert scientific review with political directives poses risks that extend far beyond vaccines.

The immediate impact of the executive order may be limited, as many pediatricians, state public health agencies, and professional medical organizations are expected to continue adhering to established immunization schedules developed through decades of scientific review and real-world experience. The order does not directly change how vaccines function, how doctors practice medicine, or how states set school vaccination requirements. Federal laws still protect these recommendations for now.

Despite this, the executive order risks confusion and uncertainty for parents and caregivers who only want to protect their children. Vaccination programs depend on the public's trust, and weakening this foundation can lead to declining vaccination rates, even if formal mandates remain unchanged. Currently, U.S. kindergarten vaccination rates are falling below the levels needed for herd immunity, a concerning trend during an ongoing measles outbreak and resurgence of other preventable infectious diseases.

The order suggests separating the combined MMR vaccine into three individual vaccines, doubling the number of shots needed for protection and increasing the number of medical visits. These practical consequences, such as more time away from work, missed school, and transportation costs, disproportionately affect families with fewer resources, less schedule flexibility, or limited healthcare access.

Moreover, the proposed separate vaccines are not yet available in the U.S., requiring manufacturers to develop new production processes, conduct testing, navigate regulatory review, and establish distribution systems. This would entail substantial costs and complexity to replace a system working effectively for decades.

The rationale behind the executive order is based on perceptions of differences in U.S. vaccine recommendations compared to those from some other developed countries, such as Denmark. However, these differences are due to varying healthcare systems, public health realities, disease prevalence, and vaccination delivery methods. Adjusting the timing and number of vaccines to suit these diverse contexts is understandable, but the order's proposal to change the U.S. schedule without scientific evidence poses significant risks to children's health and well-being.